The primary aims of the two trials were to determine a maximum-tolerated dose (MTD) for phase II dosing, assess safety, examine potential clinical activity, and examine pharmacokinetic (PK) and ...

Aprea Therapeutics has dosed a subject with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) ...

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft ...

The expansion cohort builds on the successful completion of monotherapy dose escalation and assignment of the SON-1010 maximum tolerated (MTD) dose of 1200 ng/kg. Additionally, the Company ...

Sonnet BioTherapeutics (SONN) announced safety results of SON-1010 at the highest dose combined with atezolizumab in the Phase 1b/2a clinical ...